Article
Cardiac & Cardiovascular Systems
Mary E. Roth, Melissa E. Chinn, Steven P. Dunn, Kenneth C. Bilchick, Sula Mazimba
Summary: This study found that the use of colchicine to treat acute gout in patients with acute heart failure is associated with significantly lower in-hospital mortality rates.
CLINICAL CARDIOLOGY
(2022)
Article
Chemistry, Medicinal
Berenice Stefanelli, Carmine Sellitto, Emanuela De Bellis, Martina Torsiello, Nicola Bertini, Angelo Maria Pezzullo, Graziamaria Corbi, Francesco Sabbatino, Stefano Pepe, Angela Tesse, Valeria Conti, Amelia Filippelli
Summary: This study investigates the factors causing severe hand-foot syndrome (HFS) and diarrhea in patients who do not carry the recommended DPYD single nucleotide polymorphisms (SNPs) but carry other genetic variants that increase the risk of capecitabine-related adverse drug reactions (ADRs). Through careful therapy recognition, it was discovered that the patients were taking folic acid at a dosage higher than the maximum tolerated dose during the treatment with capecitabine.
Article
Rheumatology
Soo Min Ahn, Ji Seon Oh, Seokchan Hong, Chang-Keun Lee, Bin Yoo, Yong-Gil Kim
Summary: In gout patients initiating urate-lowering therapy, low-dose colchicine showed similar efficacy in preventing gout flares compared to regular-dose colchicine, but with a lower rate of adverse events.
Article
Medicine, General & Internal
Mehdi Sheibani, Nasim Zamani, Amir Hushang Gerami, Hossein Akhondi, Hossein Hassanian-Moghaddam
Summary: This study aimed to investigate the clinical, laboratory, and electrocardiographic findings of colchicine poisoning and their correlation with respiratory/cardiovascular failure and death. The results showed that abdominal pain and hypotension at presentation were significantly correlated with mortality. Additionally, mortality was significantly associated with sinus tachycardia, hypokalemia, metabolic acidosis, and impaired liver and kidney function tests. All patients had some ECG abnormalities, with the most frequent being pathologic ST segment elevation and depression, left atrial enlargement, sinus tachycardia, PR elevation in aVR lead, and T wave inversion.
FRONTIERS IN MEDICINE
(2022)
Review
Medicine, General & Internal
Bayden J. McKenzie, Mihir D. Wechalekar, Renea Johnston, Naomi Schlesinger, Rachelle Buchbinder
Summary: The evidence suggests that low-dose colchicine may be more effective than placebo for treating acute gout, while high-dose colchicine may lead to more adverse events.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2021)
Review
Rheumatology
Lisa K. Stamp, Carl Horsley, Leanne Te Karu, Nicola Dalbeth, Murray Barclay
Summary: Colchicine plays an important role in treating various diseases, but its narrow therapeutic index makes it potentially harmful with overdose and fatalities. Strategies to minimize poisoning risk include preventing unauthorized access, intentional overdoses, and ensuring proper use. Culturally safe and appropriate education is crucial in reducing the risk of overdose.
Article
Pharmacology & Pharmacy
Bai Lv, Guobao Yang, Yejuan Wei, Yaran Lei, Yaning Ding, Wei Gong, Yuli Wang, Chunsheng Gao, Cuiyan Han
Summary: This study developed colchicine sustained-release pellets using fluidized-bed technology to prevent acute gout attacks. The pellets showed a smooth surface and spherical shape, and the release of colchicine from the pellets was similar under different pH conditions. Pharmacokinetic and pharmacodynamic studies demonstrated that the sustained-release pellets had a longer mean residence time, higher tmax, and exhibited a more optimal preventive potential against acute gout attack compared to commercial colchicine tablets. The study suggests that these sustained-release pellets provide a powerful alternative to commercial tablets.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
(2022)
Review
Medicine, General & Internal
Philip C. Robinson, Robert Terkeltaub, Michael H. Pillinger, Binita Shah, Vangelis Karalis, Eleni Karatza, David Liew, Massimo Imazio, Jan H. Cornel, Peter L. Thompson, Mark Nidorf
Summary: Long-term, low-dose colchicine has been shown to be effective in preventing gout flare and cardiovascular events without increasing risks when used in appropriate patients. Studies over the last 50 years suggest that the biologic effects of long-term colchicine do not pose additional risks.
AMERICAN JOURNAL OF MEDICINE
(2022)
Review
Rheumatology
Vicky Tai, Philip C. Robinson, Nicola Dalbeth
Summary: The COVID-19 pandemic poses challenges for people with gout due to increased risk, reduced immunogenicity, treatment prospects, and decreased quality of life. More guidance on managing gout during the pandemic and research on outcomes of COVID-19 infection in people with gout are needed.
CURRENT OPINION IN RHEUMATOLOGY
(2022)
Review
Immunology
Seyed Mahdi Seyedzadeh Sani, Mehrdad Sahranavard, Mahdi Jannati Yazdanabad, Mohsen Seddigh Shamsi, Sepideh Elyasi, Amir Hooshang Mohammadpour, Thozhukat Sathyapalan, Omid Arasteh, Vahid Ghavami, Amirhossein Sahebkar
Summary: This systematic review and meta-analysis found that co-administration of CSF with bleomycin increases the incidence of BPT. The study did not find any association between continent, bleomycin dose, cancer type, type of study, and pulmonary function test with BPT incidence.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Yongpeng Shi, Jiande Li, Ji Wang, Hanwen Cao, Huanbing Tian, FeiFei Yu, Lan Gao
Summary: This study investigated the mechanism of COL-induced diarrhea by exposing mice to COL. The results showed that COL exposure disrupted intestinal metabolic homeostasis, resulting in accumulation or depletion of various metabolites. Certain core metabolites were found to be closely related to COL-induced diarrhea and could be used as biomarkers. Changes in metabolic pathways and abnormal bile secretion were identified as important factors in COL-induced diarrhea.
CHEMICO-BIOLOGICAL INTERACTIONS
(2022)
Article
Pharmacology & Pharmacy
Yongpeng Shi, Hui Cai, Zhanyu Niu, Jiande Li, Gaowei Pan, Huanbing Tian, Li Wei, Linchi Chen, Pengfei Yang, Ji Wang, Hanwen Cao, Lan Gao
Summary: This study using a rodent model found that colchicine (COL) treatment caused severe gastric mucosal damage and significantly reduced the release of proinflammatory cytokines in the gastric mucosa. Furthermore, COL significantly disrupted the composition of gastric microbiota and reduced microbial diversity, leading to an increase in microbial biomarkers associated with diarrhea.
Article
Pharmacology & Pharmacy
Yang Liu, Xiaoruo Zhu, Shiliang Ji, Zhen Huang, Yuhui Zang, Ying Ding, Junfeng Zhang, Zhi Ding
Summary: A dissolvable colchicine-loaded microneedle was developed to deliver colchicine transdermally for preventing and treating acute gout flare. The microneedle demonstrated sufficient mechanical strength to penetrate the skin and release the drug without causing skin irritation. In vitro and in vivo experiments showed that the microneedle could deliver colchicine more effectively compared to gel. The application of the dissolvable colchicine-loaded microneedle significantly relieved pain and inflammation in an acute gout model, highlighting its potential importance in the treatment of acute gout.
Article
Critical Care Medicine
Choon Chiet Hong, Ming Chun Chan, Tianyi Wu, Mingzhou Toh, Yuan Jie Tay, Jiong Hao Tan
Summary: This study aimed to review and describe the proportion of patients with co-existing gout among patients with surgically treated septic arthritis, and compare their clinical presentation, outcomes, and complications to patients with native joint septic arthritis. The study found that patients with gout had a higher risk of complications and complexity in treatment compared to patients without gout. These findings highlight the need for further exploration of the relationship between gout and septic arthritis.
INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
(2023)
Review
Rheumatology
Eleftherios Pelechas, Vassiliki Drossou, Paraskevi V. Voulgari, Alexandros A. Drosos
Summary: Treating gout patients with colchicine alongside COVID-19 may help alleviate the symptoms, but further large-scale studies are needed to confirm this beneficial effect.
RHEUMATOLOGY INTERNATIONAL
(2021)